TMBIM4 and COVID-19: Our results suggest that the inhibition of S1R leads to morphological and transcriptional changes in human cardiac cells and, therefore, its use as a therapeutic strategy against COVID-19 should be further investigated before translated to clinical application, due to the concern of drug-induced cardiac damage and malfunction.